市場調査レポート

商品コード

1771542

血友病市場の市場規模、シェア、動向分析レポート：疾患タイプ別、治療タイプ別、治療法別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Treatment Type (On-demand, Cure), By Therapy, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日: 2025年06月10日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 883,396円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,031,866円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,328,806円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.47円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

血友病市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の血友病市場規模は2025年から2030年にかけてCAGR 6.91%を記録し、2030年には210億7,000万米ドルに達すると推定されます。

血友病治療のための遺伝子治療やモノクローナル抗体が承認され、パイプラインにそのような候補が複数存在することが市場成長の主な促進要因となっています。さらに、死亡率の低下により血友病患者の平均余命が延びていることも市場成長を促進する主要因です。

血友病をコントロールする新規治療薬の開発と上市が市場成長を促進しています。例えば、2020年4月、FDAは、青少年（12歳以上の年齢層）および成人における出血エピソードを制御する治療オプションとして、遺伝子操作製品Sevenfact［凝固第VIIa因子（遺伝子組換え）-jncw］を承認しました。さらに、バイオマリンの血友病A治療薬ロクタビアンは欧州でのみ承認されており、CSLのHemgenix（etranacogene dezaparvovec-drib）は米国と欧州の両方で承認されています。バイオマリンのロクタビアンは、前回却下された後、米国FDAで審査中であり、PDUFA期日は2023年6月30日に設定されています。

大手企業は、新製品の開発や戦略的提携に注力し、地理的プレゼンスを高めています。例えば、2022年4月、ノボ・ノルディスクA/Sはカナディアン・ブラッド・サービスと提携し、A型治療薬として市販されているエスペロクトとゾノベートの製品ラインナップを強化しました。さらに2023年2月、サノフィは血友病A治療用の血液凝固第VIII因子補充療法であるアルツビオのFDA承認を取得しました。

しかし、中国やインドなどの新興諸国では軽症から中等症の診断が遅れていることが主な阻害要因となっています。市場にとってのもう一つの主要課題は、高コストと長期データ不足のために遺伝子治療へのアクセスに問題が生じる可能性があることです。例えば、ヘムジェニックス（2022年承認）による治療費は1回あたり350万米ドルであり、世界で最も高額な治療法となっています。

血友病市場レポートハイライト

2024年の血友病市場では、血友病Aの有病率が高く、その治療に複数の製品が利用可能であることから、A型セグメントが最大のシェアを占めています。このセグメントはまた、遺伝子治療の承認により、予測期間中に最も高いCAGRで成長する見込みです。
販売チャネル別では、専門薬局が2024年に最も大きな市場シェアを占めたが、これは同疾患に必要な治療が専門的であるためです。
治療法別では、因子補充療法が2024年に血友病市場で最大のシェアを占めました。これは、予防とオンデマンド治療の両方で使用される主要な治療法であるためです。
北米は2024年に血友病市場で最大の収益を上げる地域であり、これは主要企業の存在、規制支援、患者の意識、有利な資金援助に起因しています。

治療法市場シェア、2024年と2030年
セグメントダッシュボード
世界の血友病市場：治療法別展望
市場規模と予測および動向分析、2018年～2030年
- 因子補充療法
- デスモプレシンとフィブリンシーラント
- 遺伝子治療とモノクローナル抗体

第7章血友病市場：流通チャネルの推定・動向分析

流通チャネル市場シェア、2024年および2030年
セグメントダッシュボード
世界の血友病市場：流通チャネル別望
市場規模と予測および動向分析、2018年～2030年
- 病院薬局
- 専門薬局

第8章血友病市場：地域の推定・動向分析

地域市場シェア分析、2024年および2030年
セグメントダッシュボード
世界の地域別市場のスナップショット
市場規模、予測動向分析、2018年～2030年
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- ノルウェー
- スウェーデン
- デンマーク
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

主要市場参入企業による最近の動向と影響分析
企業/競合の分類
ベンダー情勢
- 主要販売代理店およびチャネルパートナーのリスト
- Key customers
- Key company market share analysis, 2024
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Pfizer Inc.
- Bayer AG
- BioMarin
- Spark Therapeutics, Inc.
- Sanofi
- F. Hoffmann La-Roche Ltd
- Novo Nordisk A/S
- Octapharma AG.

図表

List of Tables

Table 1 List of Abbreviation
Table 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
Table 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
Table 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 17 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 18 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 19 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
Table 21 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 22 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 23 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 24 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 26 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 27 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 28 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 30 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 31 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 32 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 33 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 34 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 35 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 36 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 38 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 39 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 40 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 42 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 43 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 44 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 46 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 47 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 48 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 50 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 51 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 52 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 54 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 55 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 56 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 63 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 64 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 65 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 66 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 67 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 68 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 69 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 70 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 71 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 72 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 73 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 74 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 75 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 76 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 77 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 78 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 79 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 80 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 81 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 82 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 83 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 84 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 85 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 86 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
Table 87 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 88 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 89 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 90 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
Table 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 116 Kuwait Hemophilia Market, By Type, 2018 - 2030 (USD Million)
Table 117 Kuwait Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
Table 118 Kuwait Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
Table 119 Kuwait Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Global hemophilia market- Key market driver analysis
Fig. 7 Global hemophilia market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Global hemophilia market - Porter's analysis
Fig. 10 Global hemophilia market - PESTEL analysis
Fig. 11 Global hemophilia market type outlook key takeaways
Fig. 12 Global hemophilia market: Type movement analysis
Fig. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
Fig. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
Fig. 15 Others market estimates, 2018 - 2030 (USD Million)
Fig. 16 Global hemophilia market treatment outlook key takeaways
Fig. 17 Global hemophilia market: Treatment Type movement analysis
Fig. 18 On-demand market estimates, 2018 - 2030 (USD Million)
Fig. 19 Cure market estimates, 2018 - 2030 (USD Million)
Fig. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
Fig. 21 Global hemophilia market therapy outlook key takeaways
Fig. 22 Global hemophilia market: Therapy movement analysis
Fig. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
Fig. 24 Desmopressin & Fibrin sealants market estimates, 2018 - 2030 (USD Million)
Fig. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
Fig. 26 Regional marketplace: Key takeaways
Fig. 27 Global hemophilia market: Regional movement analysis
Fig. 28 North America hemophilia market, 2018 - 2030 (USD Million)
Fig. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
Fig. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
Fig. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
Fig. 32 UK hemophilia market, 2018 - 2030 (USD Million)
Fig. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
Fig. 34 France hemophilia market, 2018 - 2030 (USD Million)
Fig. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
Fig. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
Fig. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
Fig. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
Fig. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
Fig. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
Fig. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
Fig. 42 China hemophilia market, 2018 - 2030 (USD Million)
Fig. 43 India hemophilia market, 2018 - 2030 (USD Million)
Fig. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
Fig. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
Fig. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
Fig. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
Fig. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
Fig. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
Fig. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
Fig. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
Fig. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
Fig. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
Fig. 54 UAE market, 2018 - 2030 (USD Million)
Fig. 55 Kuwait market, 2018 - 2030 (USD Million)
Fig. 56 Strategy framework

Product Code: 978-1-68038-989-0

Hemophilia Market Growth & Trends:

The global hemophilia market size is estimated to reach USD 21.07 billion by 2030, registering a CAGR of 6.91% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights:

The type A segment held the largest share of the hemophilia market in 2024, owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy.
Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2024, attributable to the specialized nature of the treatment required for the condition
By therapy, factor replacement therapy held the largest share of the hemophilia market in 2024, as it is the major form of treatment used in both prophylaxis and on-demand treatment.
North America was the largest revenue-generating region in the hemophilia market in 2024, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Treatment
- 1.2.3. Therapy
- 1.2.4. Distribution Channel
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type
- 2.2.2. Treatment
- 2.2.3. Therapy
- 2.2.4. Distribution Channel
- 2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Hemophilia Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
3.4. Pipeline Analysis

Chapter 4. Hemophilia Market: Disease Type Estimates & Trend Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Hemophilia Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 4.4.1. Hemophilia A
  - 4.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2. Hemophilia B
  - 4.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3. Others
  - 4.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hemophilia Market: Treatment Type Estimates & Trend Analysis

5.1. Treatment Type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Hemophilia Market by Treatment Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 5.4.1. On-demand
  - 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.2. Cure
  - 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Prophylaxis
  - 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hemophilia Market: Therapy Estimates & Trend Analysis

6.1. Therapy Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Hemophilia Market by Therapy Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 6.4.1. Factor Replacement Therapy
  - 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  - 6.4.1.2. Plasma derived Factor Concentrates estimates and forecasts, 2018 - 2030 (USD Million)
    - 6.4.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    - 6.4.1.2.2. Factor VIII
      - 6.4.1.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    - 6.4.1.2.3. Factor IX
      - 6.4.1.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  - 6.4.1.3. Recombinant Factor Concentrates
    - 6.4.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      - 6.4.1.3.1.1. Factor VIII
        
        6.4.1.3.1.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      - 6.4.1.3.1.2. Factor VII
        
        6.4.1.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      - 6.4.1.3.1.3. Factor IX
        
        6.4.1.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.2. Desmopressin & Fibrin sealants
  - 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Gene Therapy & Monoclonal Antibodies
  - 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hemophilia Market: Distribution Channel Estimates & Trend Analysis

7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Global Hemophilia Market by Gender Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 7.4.1. Hospital Pharmacies
  - 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Specialty Pharmacies
  - 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Hemophilia Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
8.5. North America
- 8.5.1. U.S.
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Canada
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Mexico
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
8.6. Europe
- 8.6.1. UK
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Germany
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.3. France
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.4. Italy
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Spain
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.6. Norway
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Sweden
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Regulatory framework/ reimbursement structure
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.8. Denmark
  - 8.6.8.1. Key country dynamics
  - 8.6.8.2. Regulatory framework/ reimbursement structure
  - 8.6.8.3. Competitive scenario
  - 8.6.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
8.7. Asia Pacific
- 8.7.1. Japan
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.7.2. China
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.7.3. India
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.7.4. Australia
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.7.5. South Korea
  - 8.7.5.1. Key country dynamics
  - 8.7.5.2. Regulatory framework/ reimbursement structure
  - 8.7.5.3. Competitive scenario
  - 8.7.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.7.6. Thailand
  - 8.7.6.1. Key country dynamics
  - 8.7.6.2. Regulatory framework/ reimbursement structure
  - 8.7.6.3. Competitive scenario
  - 8.7.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
8.8. Latin America
- 8.8.1. Brazil
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework/ reimbursement structure
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.8.2. Argentina
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
8.9. MEA
- 8.9.1. South Africa
  - 8.9.1.1. Key country dynamics
  - 8.9.1.2. Regulatory framework/ reimbursement structure
  - 8.9.1.3. Competitive scenario
  - 8.9.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.9.2. Saudi Arabia
  - 8.9.2.1. Key country dynamics
  - 8.9.2.2. Regulatory framework/ reimbursement structure
  - 8.9.2.3. Competitive scenario
  - 8.9.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.9.3. UAE
  - 8.9.3.1. Key country dynamics
  - 8.9.3.2. Regulatory framework/ reimbursement structure
  - 8.9.3.3. Competitive scenario
  - 8.9.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.9.4. Kuwait
  - 8.9.4.1. Key country dynamics
  - 8.9.4.2. Regulatory framework/ reimbursement structure
  - 8.9.4.3. Competitive scenario
  - 8.9.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2024
- 9.3.4. Takeda Pharmaceutical Company Limited.
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Product benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. CSL Behring
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Product benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. Pfizer Inc.
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Product benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. Bayer AG
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Product benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. BioMarin
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Product benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. Spark Therapeutics, Inc.
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Product benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. Sanofi
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Product benchmarking
  - 9.3.10.4. Strategic initiatives
- 9.3.11. F. Hoffmann La-Roche Ltd
  - 9.3.11.1. Company overview
  - 9.3.11.2. Financial performance
  - 9.3.11.3. Product benchmarking
  - 9.3.11.4. Strategic initiatives
- 9.3.12. Novo Nordisk A/S
  - 9.3.12.1. Company overview
  - 9.3.12.2. Financial performance
  - 9.3.12.3. Product benchmarking
  - 9.3.12.4. Strategic initiatives
- 9.3.13. Octapharma AG.
  - 9.3.13.1. Company overview
  - 9.3.13.2. Financial performance
  - 9.3.13.3. Product benchmarking
  - 9.3.13.4. Strategic initiatives

血友病市場の市場規模、シェア、動向分析レポート：疾患タイプ別、治療タイプ別、治療法別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Treatment Type (On-demand, Cure), By Therapy, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

血友病市場の成長と動向：

血友病市場レポートハイライト

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章血友病市場の変数、動向、範囲

第4章血友病市場：疾患タイプの推定・動向分析

第5章血友病市場：治療タイプの推定・動向分析

第6章血友病市場：治療法推定・動向分析

第7章血友病市場：流通チャネルの推定・動向分析

第8章血友病市場：地域の推定・動向分析

第9章競合情勢

List of Tables

List of Figures

Hemophilia Market Growth & Trends:

Hemophilia Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Hemophilia Market Variables, Trends & Scope

Chapter 4. Hemophilia Market: Disease Type Estimates & Trend Analysis

Chapter 5. Hemophilia Market: Treatment Type Estimates & Trend Analysis

Chapter 6. Hemophilia Market: Therapy Estimates & Trend Analysis

Chapter 7. Hemophilia Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Hemophilia Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

血友病市場の市場規模、シェア、動向分析レポート：疾患タイプ別、治療タイプ別、治療法別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Treatment Type (On-demand, Cure), By Therapy, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

血友病市場の成長と動向：

血友病市場レポートハイライト

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 血友病市場の変数、動向、範囲

第4章 血友病市場：疾患タイプの推定・動向分析

第5章 血友病市場：治療タイプの推定・動向分析

第6章 血友病市場：治療法推定・動向分析

第7章 血友病市場：流通チャネルの推定・動向分析

第8章 血友病市場：地域の推定・動向分析

第9章 競合情勢

List of Tables

List of Figures

Hemophilia Market Growth & Trends:

Hemophilia Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Hemophilia Market Variables, Trends & Scope

Chapter 4. Hemophilia Market: Disease Type Estimates & Trend Analysis

Chapter 5. Hemophilia Market: Treatment Type Estimates & Trend Analysis

Chapter 6. Hemophilia Market: Therapy Estimates & Trend Analysis

Chapter 7. Hemophilia Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Hemophilia Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章血友病市場の変数、動向、範囲

第4章血友病市場：疾患タイプの推定・動向分析

第5章血友病市場：治療タイプの推定・動向分析

第6章血友病市場：治療法推定・動向分析

第7章血友病市場：流通チャネルの推定・動向分析

第8章血友病市場：地域の推定・動向分析

第9章競合情勢